Published • loading... • Updated
GLP-1 use among young children with obesity in US remains rare but is rising rapidly
Use remains uncommon, but prescriptions for children ages 8 to 11 rose 310-fold from 2019 to mid-2026, researchers found.
Summary by Medical Xpress
4 Articles
4 Articles
Medical XpressReposted by 
The AI Journal
The AI JournalGLP-1 use among young children with obesity in US remains rare but is rising rapidly
Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, when the drugs were first prescribed, a new study shows.
·Douglas, United Kingdom
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left2Leaning Right0Center2Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
